6.58
-0.06(-0.90%)
Currency In USD
| Previous Close | 6.64 |
| Open | 6.76 |
| Day High | 6.8 |
| Day Low | 6.48 |
| 52-Week High | 16.45 |
| 52-Week Low | 4.93 |
| Volume | 239,620 |
| Average Volume | 364,238 |
| Market Cap | 255.44M |
| PE | -1.64 |
| EPS | -4 |
| Moving Average 50 Days | 10.96 |
| Moving Average 200 Days | 9.39 |
| Change | -0.06 |
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- En
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Ja